A citation-based method for searching scientific literature

G W Reuther. Prog Mol Biol Transl Sci 2016
Times Cited: 3







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Chloé James, Valérie Ugo, Jean-Pierre Le Couédic, Judith Staerk, François Delhommeau, Catherine Lacout, Loïc Garçon, Hana Raslova, Roland Berger, Annelise Bennaceur-Griscelli,[...]. Nature 2005
100

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L Levine, Martha Wadleigh, Jan Cools, Benjamin L Ebert, Gerlinde Wernig, Brian J P Huntly, Titus J Boggon, Iwona Wlodarska, Jennifer J Clark, Sandra Moore,[...]. Cancer Cell 2005
100


Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
J Nangalia, C E Massie, E J Baxter, F L Nice, G Gundem, D C Wedge, E Avezov, J Li, K Kollmann, D G Kent,[...]. N Engl J Med 2013
66

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
P Guglielmelli, T L Lasho, G Rotunno, J Score, C Mannarelli, A Pancrazzi, F Biamonte, A Pardanani, K Zoi, A Reiter,[...]. Leukemia 2014
202
66

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Francesco Passamonti, Chiara Elena, Susanne Schnittger, Radek C Skoda, Anthony R Green, François Girodon, Jean-Jacques Kiladjian, Mary Frances McMullin, Marco Ruggeri, Carles Besses,[...]. Blood 2011
150
66

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Linda M Scott, Wei Tong, Ross L Levine, Mike A Scott, Philip A Beer, Michael R Stratton, P Andrew Futreal, Wendy N Erber, Mary Frances McMullin, Claire N Harrison,[...]. N Engl J Med 2007
901
66

A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Robert Kralovics, Francesco Passamonti, Andreas S Buser, Soon-Siong Teo, Ralph Tiedt, Jakob R Passweg, Andre Tichelli, Mario Cazzola, Radek C Skoda. N Engl J Med 2005
66

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
E Joanna Baxter, Linda M Scott, Peter J Campbell, Clare East, Nasios Fourouclas, Soheila Swanton, George S Vassiliou, Anthony J Bench, Elaine M Boyd, Natasha Curtin,[...]. Lancet 2005
66

Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
David A Hinds, Kimberly E Barnholt, Ruben A Mesa, Amy K Kiefer, Chuong B Do, Nicholas Eriksson, Joanna L Mountain, Uta Francke, Joyce Y Tung, Huong Marie Nguyen,[...]. Blood 2016
150
66


JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Elisa Rumi, Daniela Pietra, Virginia Ferretti, Thorsten Klampfl, Ashot S Harutyunyan, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Chiara Elena, Ilaria C Casetti,[...]. Blood 2014
408
33


Myeloproliferative Neoplasms: A Contemporary Review.
Ayalew Tefferi, Animesh Pardanani. JAMA Oncol 2015
199
33

Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.
C M Butcher, U Hahn, L B To, J Gecz, E J Wilkins, H S Scott, P G Bardy, R J D'Andrea. Leukemia 2008
58
33


Genetic and epigenetic complexity in myeloproliferative neoplasms.
Nicholas C P Cross. Hematology Am Soc Hematol Educ Program 2011
84
33

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Amy V Jones, Sebastian Kreil, Katerina Zoi, Katherine Waghorn, Claire Curtis, Lingyan Zhang, Joannah Score, Rachel Seear, Andrew J Chase, Francis H Grand,[...]. Blood 2005
641
33


Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
T Barbui, A M Vannucchi, V Buxhofer-Ausch, V De Stefano, S Betti, A Rambaldi, E Rumi, M Ruggeri, F Rodeghiero, M L Randi,[...]. Blood Cancer J 2015
129
33

Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Magnus Björkholm, Malin Hultcrantz, Åsa Rangert Derolf. Best Pract Res Clin Haematol 2014
36
33

STAT1 activation in association with JAK2 exon 12 mutations.
Anna L Godfrey, Edwin Chen, Charles E Massie, Yvonne Silber, Francesca Pagano, Beatriz Bellosillo, Paola Guglielmelli, Claire N Harrison, John T Reilly, Frank Stegelmann,[...]. Haematologica 2016
10
33

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Jung-Sook Ha, Yu-Kyung Kim, Soon-Il Jung, He-Ra Jung, In-Sung Chung. Ann Lab Med 2012
22
33

Emerging treatments for classical myeloproliferative neoplasms.
Alessandro M Vannucchi, Claire N Harrison. Blood 2017
64
33

DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms.
Ana P Azevedo, Susana N Silva, João P De Lima, Alice Reichert, Fernando Lima, Esmeraldina Júnior, José Rueff. Oncol Lett 2017
4
33




Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Odile Moulard, Jyotsna Mehta, Jon Fryzek, Robert Olivares, Usman Iqbal, Ruben A Mesa. Eur J Haematol 2014
122
33

Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Gamal T Ebid, Mohamed Ghareeb, Omina Salaheldin, Mahmoud M Kamel. Int J Clin Exp Pathol 2015
5
33

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
Philip A Beer, François Delhommeau, Jean-Pierre LeCouédic, Mark A Dawson, Edwin Chen, David Bareford, Rajko Kusec, Mary Frances McMullin, Claire N Harrison, Alessandro M Vannucchi,[...]. Blood 2010
212
33

Menopausal age and XRCC1 gene polymorphisms: role in breast cancer risk.
Susana N Silva, Rita Moita, Ana Paula Azevedo, Rita Gouveia, Isabel Manita, Julieta Esperança Pina, José Rueff, Jorge Gaspar. Cancer Detect Prev 2007
37
33

JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.
Alessandro M Vannucchi, Lisa Pieri, Paola Guglielmelli. Ther Adv Hematol 2011
66
33

Cell Death Signaling.
Douglas R Green, Fabien Llambi. Cold Spring Harb Perspect Biol 2015
579
33

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Thomas Stauffer Larsen, Niels Pallisgaard, Michael Boe Møller, Hans Carl Hasselbalch. Eur J Haematol 2007
109
33

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.
Camilla Nielsen, Stig E Bojesen, Børge G Nordestgaard, Klaus F Kofoed, Henrik S Birgens. Haematologica 2014
56
33

Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.
K L Rice, X Lin, K Wolniak, B L Ebert, W Berkofsky-Fessler, M Buzzai, Y Sun, C Xi, P Elkin, R Levine,[...]. Blood Cancer J 2011
31
33

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
33

Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.
Shashidhar S Jatiani, Stacey J Baker, Lewis R Silverman, E Premkumar Reddy. Genes Cancer 2010
133
33

Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.
Linda M Scott, Philip A Beer, Anthony J Bench, Wendy N Erber, Anthony R Green. Br J Haematol 2007
44
33

Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint.
José Rueff, António Sebastião Rodrigues. Methods Mol Biol 2016
62
33

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Antica Nacinović Duletić, Andrea Dekanić, Ita Hadzisejdić, Ivona Kusen, Koviljka Matusan-Ilijas, Dragana Grohovac, Blazenka Grahovac, Nives Jonjić. Coll Antropol 2012
7
33

SNPStats: a web tool for the analysis of association studies.
Xavier Solé, Elisabet Guinó, Joan Valls, Raquel Iniesta, Víctor Moreno. Bioinformatics 2006
33

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
Camilla Nielsen, Henrik S Birgens, Børge G Nordestgaard, Lasse Kjaer, Stig E Bojesen. Haematologica 2011
79
33

A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms.
Cristina Mambet, Lilia Matei, Laura Georgiana Necula, Carmen C Diaconu. J Immunoassay Immunochem 2016
3
33


Management of myelofibrosis: JAK inhibition and beyond.
Maximilian Stahl, Amer M Zeidan. Expert Rev Hematol 2017
5
33

Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression.
Pascual Bolufer, Eva Barragan, Maria Collado, José Cervera, José-Antonio López, Miguel A Sanz. Leuk Res 2006
76
33

Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study.
João Conde, Susana N Silva, Ana P Azevedo, Valdemar Teixeira, Julieta Esperança Pina, José Rueff, Jorge F Gaspar. BMC Cancer 2009
54
33



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.